The Healthcare IT, Tech + Digital Health and Private Equity teams advised Elligo Health Research on its Series D financing led by an investment affiliate of Cerner Corporation (NASDAQ: CERN) as demand for digital health continues to surge during the COVID-19 pandemic.
Elligo is a healthcare-enabling research organization that uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by the company’s Goes Direct® approach and novel IntElligo® Research Stack clinical technology, Elligo provides access to the best healthcare experts, patients, and research technologies. Elligo’s System of Accelerated Research (SOAR™) provides a model for hybrid and decentralized trials with fully remote monitoring capabilities.
Cerner is a global healthcare technology company. The company’s health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities.
The Goodwin team was led by John LeClaire.
Prior to co-founding Elligo in 2016, John Potthoff and Chad Moore served as the CEO and lead investment banker, respectively, for Theorem Clinical Research, a Nautic Partners portfolio company that Goodwin advised on its 2015 sale to Chiltern. Goodwin first advised Nautic on its acquisition of Theorem.
For more details on the Series D financing, read the press release.